Karen S. Lynch - 21 Feb 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
President and CEO, Director
Signature
/s/ Karen S. Lynch
Issuer symbol
CVS
Transactions as of
21 Feb 2022
Net transactions value
$0
Form type
4
Filing time
23 Feb 2022, 15:29:00 UTC
Previous filing
20 Dec 2021
Next filing
05 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Award $0 +257,916 +373% $0.000000 327,030 21 Feb 2022 Direct F1
holding CVS Common Stock (By Trust) 94,369 21 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Appreciation Rights 192,741 21 Feb 2022 Common Stock 192,741 $45.91 Direct F2
holding CVS Stock Appreciation Rights 93,989 21 Feb 2022 Common Stock 93,989 $37.91 Direct F3
holding CVS Stock Option 242,408 21 Feb 2022 Common Stock 242,408 $54.19 Direct F4
holding CVS Stock Option 211,196 21 Feb 2022 Common Stock 211,196 $58.34 Direct F5, F6
holding CVS Stock Option 224,604 21 Feb 2022 Common Stock 224,604 $74.30 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's Aetna Inc. 2010 Incentive Compensation Plan (the "Aetna Plan") on June 5, 2019. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 21, 2022.
F2 Represents unvested Aetna Inc. Stock Appreciation Rights ("SARs") granted under the Aetna Plan on February 17, 2017 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vest in two substantially equal annual installments beginning on February 17, 2019.
F3 Represents unvested SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F4 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F5 The number of shares subject to the option were calculated using a 30-day average price.
F6 Options became exercisable in four equal installments, commencing 4/1/2021.
F7 Option becomes exercisable in four equal installments, commencing 4/1/2022.